Roche’s Vabysmo shows sustained two-year results in difficult nAMD
Roche’s Vabysmo demonstrates sustained two-year results in difficult-to-treat neovascular age-related macular degeneration (nAMD).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.